Category Archives: Myocardial Infarction

INTRODUCTION: Uninsured patients have decreased access to care, lower rates of percutaneous coronary intervention (PCI), and worse outcomes after acutemyocardial infarction(AMI). Continue reading →

Early on in the COVID-19 pandemic, it appeared that the primary risk of death from the disease was severe pneumonia followed by a cytokine storm. As more is discovered about the disease caused by the SARS-CoV-2, an unexpected cause of death has been identifiedheart attacks and strokes caused by blood clots Continue reading →

It is well established that optimal medical therapy and invasive management are both associated with increased survival after myocardial infarction, author Claudio Montalto, MD, of the University of Pavia in Italy, said in a statement. Therefore, we then examined whether female patients had worse survival strictly due to their sexwhich means genetic and hormonal status, and so onor because of suboptimal treatment. Continue reading →

The Oregon Health Authority this week offered deeper insight into how coronavirus plays out in the state, in particular the underlying medical conditions of those who have succumbed to the illness. The state reviewed records for 73 of the 99 coronavirus-related deaths in Oregon and included the data in its latest update Tuesday. People who died from the illness may have had more than one underlying condition. Continue reading →

Be careful about reading health books. Continue reading →

1. Patients with severely reduced left ventricular ejection fraction with left main, left anterior descending, or multivessel disease who underwent percutaneous coronary intervention demonstrated higher rates of mortality and major adverse cardiovascular events compared to those who underwent coronary artery bypass grafting. Evidence Rating Level:2 (Good) There is insufficient evidence in the literature on outcomes of revascularization strategies for patients with severely reduced left ventricular ejection fraction (LVEF) Continue reading →

SAN CARLOS, Calif., April 28, 2020 (GLOBE NEWSWIRE) -- BioCardia, Inc., (BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced the issuance of United States Patent No. Continue reading →

Myocardial Infarction Drug Market report provides an in-depth analysis of the overall market over a period from 2020-2026. The Myocardial Infarction Drug Market report also provides the market impact and new opportunities created due to the COVID19 catastrophe. Download the Sample ToC and understand the COVID19 impact and be smart in redefining business strategies Continue reading →

Patients with cancer who contracted COVID-19 were more likely to present with aggressive COVID-19 disease and experience poor outcomes, according to data from a retrospective study presented at the American Association for Cancer Research (AACR) Virtual Annual Meeting I 2020.1 The study was simultaneously published in the Annals of Oncology.2 Although patients with cancer are generally considered to be particularly vulnerable to COVID-19, the clinical characteristics of patients with cancer who contract the virus is unknown. The purpose of this study was to identify clinical characteristics of these patients and to determine if there are risk factors among this population that can predict more severe COVID-19 disease. This retrospective study included data from patients hospitalized with COVID-19 infection from January 13 to February 25, 2020, from 3 designated hospitals in Wuhan, China Continue reading →

BACKGROUND: Cardiogenic shock (CS) is a severe complication ofmyocardial infarction(MI) or of takotsubo syndrome (TTS). For both diseases, CS is related to a worse long-term outcome. The outcome of CS has not been studied in a direct comparison of patients with MI and patients with TTS. Continue reading →